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Predictors of Mortality in Patients With Severe Ischemic
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Background-—Ischemic mitral regurgitation is associated with substantial risk of death. Although surgical mitral valve intervention
(MVi) may improve symptoms, it has not been shown to improve survival. The aim of this study was to identify predictors of
mortality in patients with ischemic mitral regurgitation and MVi.
Methods and Results-—We evaluated 117 consecutive patients (age, 6510 years) with advanced ischemic cardiomyopathy who
underwent cardiac magnetic resonance and subsequent MVi between January 1, 2002 and January 1, 2012. Cardiac magnetic
resonance was used to assess left ventricular remodeling and myocardial scarring. The effective regurgitant oriﬁce area was
calculated from the proximal isovelocity surface area by echocardiography. There were 43 deaths (37%) during follow-up (median,
62 months). On multivariable analysis, age ≥70 years (P=0.013), diabetes mellitus (P=0.001), dyslipidemia (P=0.012), papillary
muscle scar (P=0.010), incomplete revascularization (P=0.001), and total scar %9effective regurgitant oriﬁce area ≥0.20 cm2
(P=0.005) were each independently associated with all-cause mortality. Although patients with effective regurgitant oriﬁce area
<0.2 cm2 at baseline demonstrated an increased hazard ratio of 3.3 for every 10% increase in scar, the hazard ratio increased to 9
for every 10% increase in scar in those with baseline effective regurgitant oriﬁce area ≥0.20 cm2. Mortality also was signiﬁcantly
higher in patients with incomplete revascularization compared with those with vascularized viable myocardium (61% versus 28%;
P<0.001).
Conclusions-—Increased total scar burden and the presence of incomplete revascularization are powerful predictors of mortality in
patients with advanced ischemic cardiomyopathy undergoing MVi. Viability assessment with cardiac magnetic resonance imaging
can identify which patients with ischemic mitral regurgitation are at highest risk for mortality after surgical MVi. ( J Am Heart
Assoc. 2017;6:e007163. DOI: 10.1161/JAHA.117.007163.)
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D espite signiﬁcant advances in medical and surgicaltherapies, mortality risk associated with ischemic
mitral regurgitation (IMR) after myocardial infarction remains
high.1–4 Because the current data suggest that surgical mitral
valve intervention (MVi) provides no signiﬁcant survival
beneﬁt,5–7 much controversy remains about the role of
surgical MVi in patients with signiﬁcant IMR and severe left
ventricular (LV) dysfunction. In addition, the beneﬁt of MVi in
patients undergoing surgical revascularization continues to be
unclear, given conﬂicting evidence.8–17 Therefore, the current
guideline recommendations are based on expert opinion,
which states that surgical MVi can be performed in patients
who are undergoing cardiac surgery for other indications and
that isolated MV surgery may be considered in symptomatic
patients with severe IMR and LV dysfunction.18 However,
there are no data about which patients with IMR may derive
the most beneﬁt from MVi on the basis of the degree of
underlying myocardial scar burden. Infarct size assessed by
delayed hyperenhancement cardiac magnetic resonance
(DHE-CMR) has been a powerful predictor of adverse
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outcomes in ischemic cardiomyopathy (ICM).19,20 We sought
to determine the impact of myocardial scar burden and
incomplete revascularization on survival in patients after MVi.
Methods
Study Population
This was an observational cohort study of patients diagnosed
as having ICM (≥70% stenosis in ≥1 epicardial coronary vessel
on angiography and/or history of MI or coronary revascular-
ization)21 who were referred for clinically indicated myocardial
viability assessment with CMR between January 1, 2002 and
January 1, 2012. Patients with LV ejection fraction >40% were
excluded. Patients with standard CMR contraindications were
also not included. We identiﬁed 117 consecutive patients who
underwent MVi within 1 month after initial CMR for inclusion
in the study. Clinical variables were gathered prospectively
through medical record review. Medical treatment, coronary
revascularization (either percutaneous or surgical), and
implantable cardioverter deﬁbrillator/cardiac resynchroniza-
tion therapy implantation were recorded. Assessment of the
completeness of revascularization was determined on the
basis of the integration of coronary angiography anatomical
features, degree of myocardial scarring within these vascular
territories on CMR, and subsequent revascularization in these
corresponding vascular territories. Viable vascular territories
were deﬁned as areas with ≤50% transmural scarring based
on DHE-CMR assessment, according to the standard Amer-
ican Heart Association 16-segment model, with corresponding
major epicardial coronary artery stenosis ≥70%. Vascular
territories with >50% transmural scarring were considered
nonviable. Viable vascular territories that were not subse-
quently revascularized were considered incompletely revas-
cularized.19 The institutional review board approved
supplemental review of medical records and waived patient
consent for our study.
Clinical Outcomes
An end point of all-cause mortality was considered to be the
primary end point. Death notiﬁcation was conﬁrmed by
observation of death certiﬁcate or veriﬁed with a family
member. The duration of follow-up ranged between the time
of the CMR and August 2014.
Echocardiographic Assessment
All patients underwent comprehensive echocardiography
with commercially available instruments as part of a
standard clinical diagnostic evaluation at baseline and
follow-up. Measurements and recordings were obtained
according to the American Society of Echocardiography
recommendations.22 Severity of mitral regurgitation was
assessed using the effective regurgitant oriﬁce area (EROA),
which was calculated from the proximal isovelocity surface
area. The regurgitant volume was calculated as the product
of time-velocity integral of the regurgitant ﬂow and regur-
gitant oriﬁce area. Severe IMR was deﬁned as ≥0.2 cm2
EROA.18
CMR Assessment
CMR studies were obtained on commercially available CMR
scanners (Sonata/Avanto 1.5 T or Achieva 1.5-T XR/Ingenia
3.0-T), as previously described.20 For assessment of global
cardiac function, steady-state free precession cine images
were acquired (slice thickness, 8–10 mm in contiguous short-
axis images). LV end-systolic and end-diastolic volumes and
LV ejection fraction were calculated on short-axis cine
images. DHE-CMR images were obtained in long- and short-
axis orientations, 15 to 20 minutes after injection of
0.2 mmol/kg of gadolinium dimeglumine. DHE-CMR images
were analyzed using commercially available software (cvi42.23
Endocardial and epicardial myocardial edges were manually
delineated on DHE-CMR images. Scar was deﬁned by intensity
>2 SDs higher than user-deﬁned viable myocardium.24 The
scar percentage was automatically determined as the per-
centage of total myocardium (infarct mass/total LV mass).
Relative infarct burden within designated anterior, inferior,
Clinical Perspective
What Is New?
• Our novel ﬁndings suggest that viability assessment with
cardiac magnetic resonance provides prognostic signiﬁ-
cance in patients with ischemic cardiomyopathy who
underwent subsequent mitral valve intervention (MVi) for
signiﬁcant ischemic mitral regurgitation.
• Patients with total scar % <25% experienced improved
survival if complete revascularization was achieved concur-
rently with MVi.
• However, the mortality rate was higher in patients with total
scar % ≥25%, despite complete revascularization at the time
of MVi.
• Furthermore, patients with more severe ischemic mitral
regurgitation and increased total scar % appear to have the
highest risk of mortality, despite MVi.
What Are the Clinical Implications?
• Our study suggests that patients with total scar % ≥25% and
signiﬁcant ischemic mitral regurgitation are unlikely to
beneﬁt from MVi.
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and lateral territories was calculated as the proportion of
segmental scores contained within each territory, multiplied
by global LV infarct size, as previously described with the
standard American Heart Association 16-segment model. The
percentage of scarring in these vascular territories was
determined by dividing the infarcted mass/total ventricular
mass in the speciﬁed territory. Viable territories were deﬁned
as areas with ≤50% transmural scarring with corresponding
major epicardial coronary artery stenosis ≥70%. Vascular
territories with >50% transmural scarring were considered
nonviable. Papillary muscle infarction was deemed present if
any papillary hyperenhancement was evident on DHE-CMR
short-axis images, in accordance with established criteria.25
Mitral geometric variables were measured in 3-chamber
orientation during ventricular end systole. Tenting area
encompassed the area enclosed between the annulus and
the MV leaﬂets.
Statistical Analysis
Data are presented as meanSD. The following variables
were considered as potential predictors: demographics
(patient age and sex), cardiovascular disease risk factors
(glomerular ﬁltration rate, previous revascularization, hyper-
tension, medication, diabetes mellitus, body mass index, and
hyperlipidemia), and imaging factors from echocardiography
and CMR. Age and glomerular ﬁltration rate were negatively
correlated (r=0.57); thus, to reduce collinearity, age was
dichotomized as <70 versus ≥70 years. Also, mean tenting
area index and apical displacement were positively correlated
(r=0.62); because apical displacement was a stronger predic-
tor of mortality in the univariate analyses, it was included in
the multiple-variable analysis. Total scar % was positively
correlated with peri-infarct scar (r=0.61), anterior scar
(r=0.71), lateral scar (P=0.78), and inferior scar (r=0.50).
Because most of the scar variables were signiﬁcant predictors
of mortality in the univariate analysis, total scar was used as
the scar variable in the primary analysis. In addition, separate
models were evaluated with each of the scar variables. Cox
proportional hazards regression was used to build models of
survival time. Model assumptions, including proportional
hazards assumption, linearity, and normality, were evaluated.
Potential predictors were ﬁrst assessed in univariate analyses,
and risk factors at P>0.20 were not considered in the
multiple-variable analysis. In the multiple-variable analyses, a
backward variable selection process was used, in which 2-way
interactions with scar were considered ﬁrst; interaction terms
not signiﬁcant at P=0.05 were removed from the models. In
the ﬁnal models, only interaction terms and main effects not
involved in the interaction terms that were signiﬁcant at




We analyzed 117 patients who underwent MVi (15 under-
went MV replacement and 102 underwent MV repair).
Baseline clinical variables are summarized in Table 1. The
following concomitant procedures were also performed at
the time of MVi: 101 coronary bypass grafting procedures
(86%), 22 Dor procedures (19%), 20 left atrial appendage
closures (17%), 19 epicardial lead placements (16%), 17
tricuspid valve repairs (15%), 9 radiofrequency/cryoablation
procedures (8%), 8 aortic valve replacements (7%), and 1
patent foramen ovale closure (1%). Our study cohort was
middle aged (6510 years) and predominantly male
(73.5%), with a high prevalence of cardiovascular risk
factors. A total of 86.3% had concomitant coronary artery
bypass grafting (CABG) at the time of MVi. Most patients
received concomitant optimal medical therapies, including b
blockers, angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker, and statin. A total of 91 patients
(78%) had severe IMR (EROA, ≥0.2 cm2), and the mean
EROA at baseline was 0.310.14 cm2. Mean total scar %
was 21.216.2%, and prevalence of papillary muscle
infarction was 26% in our study group.
There were 31 patients (26%) who had at least 1
territory of incomplete revascularization: 20 patients (65%)
could not be completely revascularized because of non-
graftable epicardial coronary arteries and/or no available
conduits attributable to prior CABG; 9 patients (29%) had
areas that were clinically deemed nonviable on the basis of
surgical inspection of the myocardium and/or decision
based on the clinical MR imaging report, but met our
study’s predeﬁned criteria for viability (viable territories
were deﬁned as areas with ≤50% transmural scarring with
corresponding major epicardial coronary artery stenosis
≥70%); and 2 patients (6%) underwent concomitant positron
emission tomography studies, and the clinical decision to
not revascularize was based on the positron emission
tomography results.
Effect of Clinical Variables on Survival
There were 43 patients with events (all-cause death) during
follow-up (median, 62 months). The unadjusted hazard ratios
(HRs) obtained by Cox proportional hazards regression are
shown in Table 2. The following variables were signiﬁcant
univariate predictors of mortality: age (HR, 1.03; P=0.035),
hyperlipidemia (HR, 2.89; P=0.002), diabetes mellitus (HR,
2.65; P=0.003), incomplete revascularization (HR, 2.70;
P=0.001), peri-infarct scar (HR, 1.22; P<0.001), total scar %
(HR, 1.03; P=0.003), anterior scar % (HR, 1.03; P=0.050), and
lateral scar % (HR, 1.02; P=0.015).
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Effect of Imaging Variables on Survival
Table 3 summarizes the ﬁnal model for survival analysis.
Older age (HR, 2.64; P=0.013), presence of diabetes mellitus
(HR, 3.20; P=0.001), presence of hyperlipidemia (HR, 2.48;
P=0.012), papillary muscle infarction (HR, 3.72; P=0.010), and
incomplete revascularization (HR, 3.04; P=0.001) (Figure 1)
were each independently associated with a higher HR for
death. Patients with surgical MVi with complete revascular-
ization demonstrated signiﬁcantly improved survival com-
pared with those with incomplete revascularization.
Differential survival is seen immediately, and survival curves
continue to further separate over time.
In addition, there was a signiﬁcant interaction between
amount of total scar % and EROA at baseline (Figure 2). In
Table 1. Baseline Clinical Variables
Variables MVi
No. of patients 117
Age, mean (SD), y 64.8 (10.4)
Male sex, % 73.5
Body mass index, mean (SD), kg/m2 28.7 (5.6)
Hypertension, % 55.7
Diabetes mellitus, % 19.7
Hyperlipidemia, % 51.3
Statin, % 74.1
b Blocker, % 83.3
ACE inhibitor or ARB, % 77.8
Spironolactone, % 23.9
Loop diuretics, % 35.0
Aspirin, % 89.0
GFR, mean (SD), mL/min per 1.73 m2 84.3 (37.6)
CAD characteristics, %






Total scar, mean (SD), % 21.2 (16.2)
Anterior scar, mean (SD), % 24.8 (23.5)
Lateral scar, mean (SD), % 14.6 (18.7)
Inferior scar, mean (SD), % 18.5 (21.6)
Peri-infarct scar, mean (SD), % 5.4 (2.9)
Papillary muscle infarction, % 24.4
LVESVi, mean (SD), mL/m2 114.0 (34.9)
LVEF, mean (SD), % 23.0 (8.5)
Tenting area index, mean (SD), cm2/m2 0.84 (0.43)
Apical displacement, mean (SD), cm 0.53 (0.21)
Echocardiographic variable
EROA at baseline, mean (SD), cm2 0.31 (0.14)
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker;
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CRT, cardiac
resynchronization therapy; EROA, effective regurgitant oriﬁce area; GFR, glomerular
ﬁltration rate; ICD, implantable cardioverter deﬁbrillator; LVEF, left ventricular ejection
fraction; LVESVi, left ventricular end-systolic volume index; MRI, magnetic resonance
imaging; MVi, mitral valve intervention; and PCI, percutaneous coronary intervention.
*n=49. The time between MRI and ICD was <6 months for 57% of patients, and ranged
from 0.5 to 6 years for the remaining patients.
†n=20. The time between MRI and CRT was <6 months for 50% of patients, and ranged
from 0.5 to 6 years for the remaining patients.
Table 2. Univariate Predictors of Outcomes
Predictor HR (95% CI) P Value
Age 1.03 (1.00–1.07) 0.035
Male sex 0.54 (0.29–1.01) 0.054
Body mass index 0.99 (0.94–1.05) 0.844
ACE-i 1.14 (0.53–2.45) 0.743
Lasix 0.83 (0.45–1.56) 0.573
Hyperlipidemia 2.89 (1.49–5.59) 0.002
Hypertension 1.45 (0.77–2.72) 0.247
Diabetes mellitus 2.65 (1.39–5.08) 0.003
Statin 1.00 (0.50–2.00) 0.998
Spironolactone 0.72 (0.34–1.57) 0.413
Aspirin 1.01 (0.55–1.85) 0.974
GFR 0.99 (0.98–1.00) 0.117
No. of vessels of CAD 1.16 (0.82–1.65) 0.411
Incomplete revascularization 2.70 (1.47–4.95) 0.001
CRT† 1.22 (0.60–2.47) 0.590
ICD† 0.78 (0.43–1.44) 0.426
Mean tenting area index 0.70 (0.33–1.47) 0.343
Mean apical displacement 0.31 (0.05–1.75) 0.184
LVESVi 0.99 (0.98–1.00) 0.194
LVEF 1.01 (0.97–1.05) 0.710
Total scar % 1.03 (1.01–1.05) 0.003
Anterior scar % 1.01 (1.00–1.03) 0.050
Lateral scar % 1.02 (1.00–1.03) 0.015
Inferior scar % 1.00 (0.99–1.02) 0.858
Peri-infarct scar % 1.22 (1.13–1.33) <0.001
Papillary muscle infarction 2.13 (0.94–4.766) 0.067
EROA ≥0.20 cm2 at baseline 0.42 (0.16–1.07) 0.068
ACE-i indicates angiotensin-converting-enzyme; CAD, coronary artery disease; CI,
conﬁdence interval; CRT, cardiac resynchronization therapy; EROA, effective regurgitant
oriﬁce area; GFR, glomerular ﬁltration rate; HR, hazard ratio; ICD, implantable
cardioverter deﬁbrillator; LVEF, left ventricular ejection fraction; and LVESVi, left
ventricular end-systolic volume index.
†Time-dependent covariates.
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particular, among patients with ERO <0.20 at baseline, for
every 10% increase in total scar, the HR for mortality was 3.3.
In contrast, the HR was 9 for every 10% increase in scar
among patients with ERO ≥0.20. Patients with a smaller
myocardial scar burden demonstrated improved survival
compared with those with greater scar burden. Patients with
lower scar burden and less IMR had better survival than those
with lower scar burden and more signiﬁcant IMR. In addition,
patients with lower scar burden and more signiﬁcant IMR had
better survival than patients with higher scar burden and less
signiﬁcant IMR. On the other hand, patients with increased
scar burden had signiﬁcantly worse survival, regardless of the
severity of IMR before MVi.
Discussion
Optimal management of patients with advanced ICM and
signiﬁcant IMR continues to be unclear, and much controversy
remains about which therapeutic interventions will provide the
best outcomes and sustainable relief of symptoms. This
present study sought to determine the prognostic utility of
viability assessment with CMR imaging in patients with
advanced ICM and signiﬁcant IMR who underwent subsequent
MVi. The results of this study demonstrate the following novel
ﬁndings: (1) increased total myocardial scar burden and
incomplete revascularization are powerful independent pre-
dictors of mortality in patients with advanced ICM and IMR
Table 3. Final Model for Outcomes
Independent Variable HR (95% CI) P Value
Hyperlipidemia 2.48 (1.23–5.01) 0.012
Diabetes mellitus 3.20 (1.60–6.40) 0.001
EROA ≥0.20 cm2 at baseline 6.55 (0.53–81.5) 0.144
Age ≥70 y* 2.64 (1.22–5.70) 0.013
Papillary muscle infarction 3.72 (1.37–
10.12)
0.010
Total scar % 1.13 (1.06–1.20) <0.001
Incomplete revascularization 3.04 (1.54–5.99) 0.001
Total scar9EROA ≥0.20 cm2 at baseline 0.92 (0.86–0.97) 0.005
CI indicates conﬁdence interval; EROA, effective regurgitant oriﬁce area; and HR, hazard
ratio.
*Age ≥70 years relative to age <70 years. Note that similar results were obtained when
age was treated as a continuous variable in the model.
Figure 1. Event-free survival by presence/absence of incom-
plete revascularization: patients with complete revascularization
(blue curve, N=86, with 24 events) and patients with incomplete
revascularization (red curve, N=31, with 19 events). IR indicates
incomplete revascularization.
Figure 2. Event-free survival by baseline total scar and effective
regurgitant oriﬁce area (EROA): patients with baseline total scar
<25% and EROA <0.20 cm2 (blue curve, N=15), patients with
baseline total scar <25% and EROA ≥0.20 cm2 (red curve, N=64),
patients with baseline total scar ≥25% and EROA <0.20 cm2
(green curve, N=11), and patients with baseline total scar ≥25%
and EROA ≥0.20 cm2 (orange curve, N=27). At 500 days, there
were 13 patients with total scar <25% and EROA <0.20 cm2 at
risk, 60 patients with total scar <25% and EROA ≥0.20 cm2 at
risk, 9 patients with total scar ≥25% and EROA <0.20 cm2 at risk,
and 23 patients with total scar ≥25% and EROA ≥0.20 cm2 at risk.
At 1000 days, there were 12 patients with total scar <25% and
EROA <0.20 cm2 at risk, 44 patients with total scar <25% and
EROA ≥0.20 cm2 at risk, 6 patients with total scar ≥25%
and EROA <0.20 cm2 at risk, and 20 patients with baseline total
scar ≥25% and EROA ≥0.20 cm2 at risk. At 2000 days, there were
8 patients with total scar <25% and EROA <0.20 cm2 at risk, 26
patients with total scar <25% and EROA ≥0.20 cm2 at risk, 2
patients with total scar ≥25% and EROA <0.20 cm2 at risk, and 13
patients with total scar ≥25% and EROA ≥0.20 cm2 at risk.
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who underwent MVI; and (2) signiﬁcant interaction between
baseline EROA and total scar burden independently predicts
mortality. We found that the risk associated with IMR was
modulated by the amount of underlying myocardial scar
burden. However, patients with increased myocardial scar
burden had signiﬁcantly worse survival than those with less
myocardial scar burden, regardless of the severity of IMR
before MVi.
Effect of Viability Assessment With CMR on
Survival
Although IMR has been shown to be a well-established
predictor of mortality, unfortunately, several studies have
suggested that surgically reducing the severity of IMR does
not result in improved survival.6,7,26–28 Furthermore, there are
conﬂicting data in the literature about the impact of CABG
alone versus CABG+MVi for the treatment of IMR and whether
MVi results in improved survival,8–17 symptoms, or LV
remodeling.26–28 The uncertain beneﬁt of MVi for signiﬁcant
IMR suggests that the risk associated with increasing degrees
of IMR may be more a reﬂection of greater adverse LV
remodeling and subsequent annular dilation, impaired coap-
tation, and lateral displacement of the papillary muscles
attributable to myocardial infarction in patients.
Despite the controversy over the beneﬁt of MVi for IMR,
patients with IMR are frequently referred for coronary
revascularization+MVi. Viability assessment before CABG
and CABG+MVi was not included in prior studies in the
literature. Differences in outcome between CABG and
CABG+MVi among the published studies may, in part, reﬂect
differences in (1) the severity of underlying myocardial scar
and (2) completeness of revascularization. Furthermore, prior
studies have not included an assessment of incomplete
revascularization in their survival analysis.
Our study demonstrates the importance of complete
revascularization of viable myocardium in patients with
advanced ICM and signiﬁcant IMR undergoing MVi. This
ﬁnding supports a large retrospective observational study that
suggested that surgical revascularization may provide signif-
icant survival beneﬁt in this patient population.9 Castleberry
et al9 found that patients who underwent CABGMVi expe-
rienced improved survival compared with patients who
underwent percutaneous coronary intervention and/or med-
ical therapy alone. Although this study did not demonstrate
signiﬁcant survival beneﬁt in patients who underwent CABG
versus CABG+MVi, a STICH (Surgical Treament for IsChemic
Heart failure) substudy suggested that CABG+MVi may
provide survival beneﬁt compared with CABG alone in patients
with signiﬁcant IMR. However, a viability assessment to
examine the possibility of differential outcomes in patients
with increased scar burden was not performed in either of
these analyses. The mean ejection fractions in our study and
in the STICH substudy were signiﬁcantly lower compared with
those of prior randomized control studies, suggesting that
CABG+MVi may be more beneﬁcial in patients with more
advanced LV dysfunction and adverse remodeling, but
signiﬁcant viability.
The current study demonstrates the powerful prognostic
ability of myocardial scar quantiﬁcation with DHE–MR imaging
to predict outcomes; patients who underwent MVi with
smaller areas of myocardial infarction experienced more
favorable outcomes after MVi compared with those with
larger areas of myocardial infarction. In addition, patients with
smaller areas of myocardial infarction with less signiﬁcant
IMR demonstrated >75% survival, whereas patients with
larger areas of myocardial infarction had <50% survival over a
median follow-up of 5.2 years. We have previously demon-
strated increasing survival beneﬁt with CABG in patients with
increased scar burden.20 However, most patients in our prior
study did not undergo MVi, and the relationship of myocardial
scarring to the location of epicardial coronary artery disease
was not available. Therefore, the completeness of revascu-
larization of viable myocardium was not included in our
previous analysis.
The current study demonstrates the importance of relating
the location of myocardial scarring with coronary artery
anatomical features. Complete revascularization of viable
myocardium in the setting of signiﬁcant IMR likely improves
outcomes by decreasing the ischemic burden attributable to
the increased wall stress associated with adverse LV remod-
eling and IMR. It also provides greater potential for improved
myocardial function in the viable segments, regression of
hypertrophy and end-systolic volume index, and potential
stabilization of increased arrhythmic substrate. Our current
data demonstrate that patients undergoing MVi with large
areas of myocardial infarction and more severe IMR experi-
ence the highest rate of mortality.
Much controversy remains about the utility of viability
testing in patients with advanced ICM. However, there are no
studies that have evaluated the impact of viability testing
speciﬁcally in patients with signiﬁcant IMR. Our study
suggests that incompletely revascularized viable myocardium
is an independent predictor of increased mortality in patients
with signiﬁcant IMR undergoing MVi. This ﬁnding conﬁrms the
recommendations to make every effort to completely revas-
cularize patients with advanced ICM and signiﬁcant IMR.18,29
Most patients in our study population (86%) underwent
concomitant surgical revascularization. However, complete
revascularization was not possible in a minority of patients
(26%) because of poor-quality epicardial vessels with diffuse
disease and/or lack of adequate conduits for surgical bypass
grafts. These patients with incompletely revascularized viable
myocardium demonstrated a signiﬁcantly higher rate of
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mortality. Further studies are needed to determine if hybrid
procedures, with combined CABG+percutaneous interven-
tions to achieve complete revascularization, versus advanced
therapies, such as LV assist device or heart transplant, may
provide signiﬁcantly improved survival in patients with
advanced ICM and signiﬁcant MR with poor epicardial
coronary artery targets.
This study revealed a novel interaction between the amount
of total scar % and EROA at baseline in patients who
subsequently underwent surgical MVi. There was a 3.3-fold
increase in risk for every 10% increase in total scar burden for
patients with less signiﬁcant IMR, with ERO <0.20. In contrast,
there was a 9-fold increase in risk in mortality for every 10%
increase in scar among patients with an ERO ≥0.20. Therefore,
the risk associated with IMR is signiﬁcantly modulated by the
degree of myocardial scarring. Patients with lower scar burden
and less signiﬁcant degree of IMR demonstrated better
survival that those with lower scar burden and more signiﬁcant
IMR. On the other hand, patients with increased myocardial
scarring with signiﬁcant IMR have signiﬁcantly worse survival
compared with patients with the same degree of IMR with less
scarring. In addition, patients with lower scar burden and more
signiﬁcant IMR had better survival than patients with higher
scar burden and less signiﬁcant IMR. This ﬁnding suggests that
patients with lower EROA may have developed adaptive
abilities to abate the risk associated with increased myocardial
scar burden. On the other hand, patients with increased scar
burden had signiﬁcantly worse survival, despite the severity of
IMR before MVi. Higher mortality in the setting of more severe
IMR and increased total scar % likely reﬂects the inability for
the LV to adapt to IMR, regardless of the severity, because of
increased myocardial scar burden. Higher EROA, reﬂecting
more severe IMR, likely results in further maladaptive LV
remodeling, higher wall stress attributable to higher ﬁlling
pressures, and higher risk of mortality in the setting of
increasing myocardial scar burden. These ﬁndings suggest
that the quantiﬁcation of myocardial scar burden provides
incremental risk stratiﬁcation in patients with signiﬁcant IMR
and advanced LV remodeling.
Further studies are needed to determine if MVi should be
considered at an earlier stage in patients with smaller areas of
myocardial infarction, but with signiﬁcant LV dysfunction. In
addition, further studies are needed to determine if advanced
therapies, such as LV assist device or heart transplant, may
provide survival beneﬁt in patients with large areas of
myocardial infarction.
Clinical Implication
IMR is an extremely complex process, with continued
controversy about optimal treatment. Our study is the ﬁrst
to demonstrate the prognostic signiﬁcance of viability
assessment with CMR in patients with advanced ICM who
underwent subsequent MVi for signiﬁcant IMR. Our study
demonstrates that assessment of viability with CMR may
provide important prognostic information, which may help to
customize the optimal treatment strategy for each patient.
Total myocardial scar burden, incomplete revascularization
assessed by viability evaluation with CMR, and an interaction
between baseline IMR severity and scar burden may identify
the highest-risk patients. Patients with myocardial scar
burden <25%, with adequate epicardial vessels and surgical
bypass grafts, appear to experience favorable survival if
complete revascularization is achieved at the time of MVi. On
the other hand, patients with myocardial scar burden ≥25%
appear to have poor survival, despite the ability to achieve
complete revascularization at the time of MVi. In addition,
patients with more severe IMR in the setting of increased
myocardial scar burden appear to have the highest risk of
mortality, despite MVi. Therefore, our study suggests that
further studies are needed to determine if patients with
myocardial scar burden ≥25% in the setting of signiﬁcant IMR
should be considered for advanced therapies, such as LV
assist device or heart transplant, rather than MVi.
Limitations
This was an observational, single-center study that only
included patients with advanced ICM, who were able to
undergo DHE-CMR study. In addition, only patients who
underwent MV repair or replacement at our institution after
the baseline CMR were included. Furthermore, the CMR
ﬁndings may have inﬂuenced the clinicians’ decision to refer
patients for surgical MVi. Patients with prior device implan-
tation were excluded from this study because of contraindi-
cations for CMR, Therefore, signiﬁcant selection bias may be
present.
Assessment for optimal medical therapy in our patient
population was complex, because medical therapy changed in
a signiﬁcant portion of our population during follow-up.
Although additional medications were added to optimize the
medical regimen during follow-up in a proportion of our
patients, some medications were discontinued because of
relative hypotension or development of acute renal failure/
hyperkalemia/elevated liver enzymes postoperatively. In
addition, it is possible that some patients may have under-
gone cardiac resynchronization therapy/implantable car-
dioverter deﬁbrillator implantation outside of our institution.
The limited follow-up data may affect the results of our study.
Therefore, further studies are needed to determine how the
risk of incomplete revascularization and increased scar
burden is mitigated by optimal medical therapy and cardiac
resynchronization therapy/implantable cardioverter deﬁbrilla-
tor when compared with surgical revascularization and MVi.
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All-cause mortality was used as the primary end point in
our patient population. The most likely cause of death in our
patient population is cardiac, given the known high risk nature
of our patient population. Although discerning how incomplete
revascularization and increased scar burden is associated
with risk of sudden cardiac death, myocardial infarction, or
pump failure would be of important interest, determining the
deﬁnitive cause of death by death certiﬁcates can be difﬁcult
in such a high-risk population, and can pose a source of bias.
Despite the limitations, this is the largest study of patients
who have undergone CMR before MVi in the literature. We
believe that the ﬁndings of this study reveal important
ﬁndings about the prognostic utility of viability assessment
with CMR in patients with signiﬁcant IMR undergoing
evaluation for MVi.
Conclusions
Increased total scar burden and the presence of incomplete
revascularization are powerful predictors of mortality in
patients with advanced ICM undergoing MVi. Viability assess-
ment with CMR imaging can identify which patients with IMR
are at highest risk for mortality after surgical MVi.
Complete revascularization in the setting of small myocar-
dial scar burden appears to be associated with favorable
survival in patients undergoing MVi for signiﬁcant IMR.
Patients with large myocardial scar burden appear to have
the highest risk of death, and further studies are needed to
determine if these patients would derive survival beneﬁt from
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